We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Vitamin D Supplementation on Patients With Type 2 Diabetes and Vitamin D Deficiency (VDD)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2015 by avraham ishay, HaEmek Medical Center, Israel.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01991054
First Posted: November 25, 2013
Last Update Posted: July 17, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
avraham ishay, HaEmek Medical Center, Israel
  Purpose

Vitamin D plays a key role in keeping normal mineral balance and maintaining bone health. There is accumulating evidence linking deficient vitamin D status with both type 1 and type 2 diabetes.

The purpose of this study is to evaluate the effect of high dose vitamin D supplementation (120000 units per month)for 6 months on glucose homeostasis and glycemic control,in vitamin D deficient patients with non-optimally controlled type 2 diabetes mellitus.


Condition Intervention Phase
Diabetes Mellitus Vitamin D Deficiency Dietary Supplement: vitamin D3 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Double Blind, Randomized, Phase 4, Clinical Trial of The Effects of Vitamin D Supplementation on Patients With Type 2 Diabetes and Vitamin D Deficiency

Resource links provided by NLM:


Further study details as provided by avraham ishay, HaEmek Medical Center, Israel:

Primary Outcome Measures:
  • Change in Hba1c (%) in study groups [ Time Frame: 2 years ]
    We assume that the treatment with vitamin D will improve diabetes control, as assessed by Hba1c . The expected reduction in Hba1c levels will be 0.5%.


Secondary Outcome Measures:
  • Lipid profile [ Time Frame: 2 years ]
    Total cholesterol, LDL choleterol , HDL cholesterol, non HDL cholesterol, Triglycerides

  • C-reactive protein [ Time Frame: 2 years ]
  • Body Weight [ Time Frame: 2 years ]
  • Blood Pressure [ Time Frame: 2 years ]
  • serum calcium [ Time Frame: 2 years ]
  • serum phosphore [ Time Frame: 2 years ]
  • serum PTH [ Time Frame: 2 years ]
  • serum creatinine [ Time Frame: 2 years ]
  • serum albumin [ Time Frame: 2 years ]

Estimated Enrollment: 180
Study Start Date: December 2013
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: vitamin D3 supplementatio
The study group participants will receive vitamin D3 supplementation (120,000 I.U per month)for 6 months
Dietary Supplement: vitamin D3
Other Name: Cholecalciferol
Placebo Comparator: placebo group
placebo group, 15 ml per month for 6 months

Detailed Description:

This is a randomized, double blind, parallel group, clinical trial for 6 months duration.

The study group participants will receive vitamin D supplementation (120,000 IU per month) versus the placebo group for 6 months. glycemic control indexes will be measured in T2DM diagnosed study subjects.

Patient will be randomized 1:1 to one of two treatment groups. Vitamin D group vs placebo group.

Randomization kits will include either vitamin D or vitamin D placebo. Blood screens will be taken prior, after 3 months from randomization and after 6 months from randomization. Anthropometric measurements will be drawn as well, at the same time points.

Determination of sample size In order to find a 0.5 mean difference in HgA1C between the two treatment arms (standard deviation 1.2) a 184 sample size will be required to achieve 80% power, 5% alpha (two sided test).

ADMINISTRATIVE AND LEGAL OBLIGATIONS:

Individual patient's medical information obtained as result of this study is considered confidential and disclosure to third parties.

The investigator should maintain a list of appropriately qualified people to whom trail duties are delegated.

Source and study documents will be locked under the supervision of the PI- principle investigator for 15 years.

Study documentations and storage The investigator should maintain a list of appropriately qualified people to whom trail duties are delegated.

All persons authorized to make entries and/or correction on CRF will be included on the investigators team list delegation log.

Study printout and electronic CRF's, ICF's and other study documents will be stored in the at Haemek medical center under the supervision of the PI. All identifying details will be completely erased.

The investigator and staff are responsible for maintaining a comprehensive and centralized filing system of all study- related documentation, suitable for inspection at any time.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written inform consent must be obtained from the patient before any assessment is performed.
  • Male or female patient, 18 years or older.
  • Diabetes mellitus patients.
  • HgA1C levels on randomization above 7.5% in the last 6 months.
  • Low 25(OH) vitamin D levels : under 50nmol/l

Exclusion Criteria:

  • Patient who are unable consume food orally.
  • Life expectancy under 7 month.
  • Unable to sign inform consent.
  • Patient unwilling or unable to comply with study procedure.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01991054


Contacts
Contact: avraham ishay, M.D 972 46494000 ext 5556 ishay_av@clalit.org.il
Contact: hila kfir, b.sc 972 46494000 ext 5559 hila_kf@clalit.org.il

Locations
Israel
Haemek medical center, endocrone clinic Recruiting
Afula, Israel, 1834111
Contact: avraham ishay, M.D    972 46494000 ext 5556    ishay_av@clalit.org.il   
Contact: hila kfir, b.sc    972 46494000 ext 5559    hila_kf@clalit.org.il   
Principal Investigator: avraham ishay, M.D         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: avraham ishay, M.D haemek medical center
  More Information

Additional Information:
Publications:

Responsible Party: avraham ishay, endocronologist, HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT01991054     History of Changes
Other Study ID Numbers: HGA1C vs D
First Submitted: November 7, 2013
First Posted: November 25, 2013
Last Update Posted: July 17, 2015
Last Verified: July 2015

Keywords provided by avraham ishay, HaEmek Medical Center, Israel:
Diabetes mellitus
HgA1C
25(OH) vitamin D
HgA1C levels above 7.5%

Additional relevant MeSH terms:
Diabetes Mellitus
Vitamin D Deficiency
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents